secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aspire Biopharma Holdings, Inc. (ASBP)
CIK:        0001847345
Form:       8-K
Filed at:   2026-09-29T21:15:13+00:00
Accession:  0001493152-26-044908
Event type: other_material
Sentiment:  negative
Materiality: 0.45
Item codes: 4.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Aspire-Lakewood swaps auditors: Turner Stone out, CBIZ in; prior FY2025 opinion carried going-concern note
--------------------------------------------------------------------------------

- Audit Committee dismissed Turner Stone & Company, LLP on September 24, 2026 after a FY2025 report that included an explanatory paragraph on substantial doubt about going-concern status.
- CBIZ CPAs P.C. approved as new independent registered public accounting firm for the fiscal year ending December 31, 2026, effective immediately.
- No disagreements on accounting principles, disclosure or audit scope, and no Item 304(a)(1)(v) reportable events for the year ended December 31, 2025 or interim periods through September 24, 2026.
- Company had disclosed material weaknesses in internal control over financial reporting as of December 31, 2025, with disclosure controls and procedures deemed not effective (Form 10-K Item 9A).
- Turner's letter to the SEC, dated September 29, 2026, states it does not disagree with the Company's statements; filed as Exhibit 16.1.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1847345/000149315226044908/0001493152-26-044908-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1847345/000149315226044908/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-044908

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer